Phaseline

Companies › Kumquat Biosciences

Kumquat Biosciences: clinical trials, targets and expected readouts

5 active drug programs in 8 registered trials: 7 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KQB198–Phase 2GIST - Gastrointestinal Stromal Tumor; Solid Tumor, Adult; Hematologic Malignancies; KRAS G12C MutationDec 2026
KQB548
KRAS G12D inhibitor
KRASPhase 1Solid Tumor MalignanciesMar 2027
KQB168–Phase 1Solid Tumor MalignanciesNov 2027
KQB365–Phase 1KRAS G12C MutationJun 2029
KQB368–Phase 1Advanced Solid TumorsDec 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06507306KQB198Phase 1Solid Tumor, AdultOncologyDec 2026
NCT06645886KQB198Phase 1Hematologic MalignanciesOncologyMar 2027
NCT07207707KQB548Phase 1Solid Tumor MalignanciesOncologyMar 2027
NCT07406633KQB198Phase 2GIST - Gastrointestinal Stromal TumorOncologyOct 2027
NCT06994806KQB168Phase 1Solid Tumor MalignanciesOncologyNov 2027
NCT06720987KQB365Phase 1KRAS G12C MutationOncologyJun 2029
NCT06720987KQB198Phase 1KRAS G12C MutationOncologyJun 2029
NCT07542704KQB368Phase 1Advanced Solid TumorsOncologyDec 2029

Targets

KRAS (1)

Companies with the same targets

Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly Bristol-Myers Squibb Amgen Novartis Astellas Abbisko Therapeutics

Companies built like this

Genfleet Therapeutics (Shanghai) Ranok Therapeutics (Hangzhou) Vividion Therapeutics Jacobio Pharmaceuticals Erasca

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.